Drugs / rAd5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00961883 | Aug 2009 → Jan 2013 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT00801697 | Feb 2009 → Feb 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAd5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00961883 ↗ |
| Known as | Recombinant adenoviral serotype 5 | “Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU” NCT00961883 ↗ |
| Modality | Vaccine | “recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAD5) HIV-1 vaccines” NCT00801697 ↗ |
| Route | Intramuscular | “rAd5 intramuscularly at Month 6” NCT00801697 ↗ |